Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dorsal root ganglia homeobox protein (DRGX) is a transcription factor that binds sequence-specific double-stranded DNA and regulates gene expression essential for the development and correct projection of nociceptive sensory neurons in the dorsal horn of the spinal cord, contributing to normal pain perception and sensory nervous system development. It is not currently considered a therapeutic target, with no known direct drug interactions or use as a biomarker. Mutations or deletions involving DRGX may be associated with neurodevelopmental and myasthenic syndromes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dorsal root ganglia homeobox protein (DRGX).